DDX53 and neoplasm: Accordingly, the improved specificity of tumor-targeted drug delivery by PPA1-DOX renders itself a significantly increased antitumor activity, as demonstrated by improved tumor growth inhibition and prolonged survival time in PPA-DOX-treated CT26 bearing mice, in comparison with RAN-DOX-treated group (Figures 5B, C).